Caliper Life Sciences to Discuss Next Generation Tools for Breakthrough Medical Research at BioConference Live
HOPKINTON, Mass., June 2 /PRNewswire-FirstCall/ — Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced President and CEO Kevin Hrusovsky will present at the BioConference Live Webinar today, June 2, 2010 at 11:00 a.m. ET. Hrusovsky’s keynote presentation, “Next Generation Tools Enabling a Revolution in Medicine,” will discuss how advances in preclinical technologies are translating experimental research into safe and effective therapies for a wide range of diseases.
Caliper’s technologies have helped pharmaceutical and biotechnology researchers worldwide bring novel drugs to market. During the BioConference Live presentation, Hrusovsky will discuss the need for better therapeutics and provide an overview of how innovative technologies, including next generation sequencing, optical imaging and microfluidics, are accelerating experimentation with biomarkers, biotherapeutics, vaccines and stem cells and providing researchers with a detailed understanding of disease development and biologic response.
Who: Caliper Life Sciences What: BioConference Live Webinar When: Wednesday, June 2, 2010, 11:00 a.m. ET Where: www.bioconferencelive.com
Taking place June 2-3, 2010, BioConference Live is an online conference for the life sciences and biotechnology community featuring video keynote presentations from industry thought leaders, a virtual exhibit hall and poster sessions where researchers will present and discuss their latest work. To register, or for additional details, please visit www.bioconferencelive.com.
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper’s portfolio of offerings includes state-of-the-art microfluidics, lab automation and liquid handling, optical imaging technologies, and discovery and development outsourcing solutions. For more information please visit www.caliperLS.com.
SOURCE Caliper Life Sciences, Inc.